Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

David Jung, Holly Lee, Sejal Chikhale, Mansour Poorebrahim, Sungwoo Ahn, Sacha Benaoudia, Noemie Leblay, Francesco Maura, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 591.

https://doi.org/10.1182/blood-2024-206347

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Marios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, Holly Lee, John McIntyre, Marietta Truger, Michael Durante, Bachisio Ziccheddu, Ola Landgren, Leo Rasche, Nizar J. Bahlis, Paola Neri, Francesco Maura

Blood (2024) 144 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2024-212294

Published: 2024

Journal Articles

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

Holly Lee, Sungwoo Ahn, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Noémie Leblay, Francesco Maura, Lawrence H. Boise, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2024-211979

Published: 2024

Journal Articles

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Holly Lee, David Jung, Mansour Poorebrahim, Sacha Benaoudia, Sungwoo Ahn, Noémie Leblay, Eric Letouzé, Philippe Moreau, Herve Avet-Loiseau, Leo Rasche, Jonathan J Keats, Francesco Maura, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2024-211833

Published: 2024

Journal Articles

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Noémie Leblay, Sungwoo Ahn, Holly Lee, Matteo Claudio Da Vià, Mansour Poorebrahim, Sacha Benaoudia, David Jung, Elham Hasheminasabgorji, Niccolò Bolli, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2024-208842

Published: 2024

Journal Articles

Plasma cells’ fate: it is a complex “orchestra”

Paola Neri

Blood (2024) 144 (5): 466–467.

https://doi.org/10.1182/blood.2024025016

Published: 2024

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 function over forms in multiple myeloma

Paola Neri, Lawrence H. Boise

Blood (2024) 143 (13): 1202–1204.

https://doi.org/10.1182/blood.2023023487

Published: 2024

Journal Articles

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Noémie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence H. Boise, Nizar Bahlis, Paola Neri

Blood (2024) 143 (1): 42–56.

https://doi.org/10.1182/blood.2023020276

Published: 2024

Includes: Supplemental data

Journal Articles

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

Mansour Poorebrahim, Holly Lee, Sacha Benaoudia, Ranjan Maity, Sungwoo Ahn, Noémie Leblay, Elie Barakat, Remi Tilmont, Douglas Mahoney, Lawrence H. Boise, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 454.

https://doi.org/10.1182/blood-2023-189747

Published: 2023

Journal Articles

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Holly Lee, Michael Durante, Sungwoo Ahn, Noemie Leblay, Mansour Poorebrahim, Ranjan Maity, Rémi Tilmont, Elie Barakat, David Jung, Bachisio Ziccheddu, Alexis Brake, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2023-188080

Published: 2023

Journal Articles

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Holly Lee, Sungwoo Ahn, Ranjan Maity, Noémie Leblay, Michael Durante, Bachisio Ziccheddu, Alexis Brake, Remi Tilmont, Elie Barakat, Mansour Poorebrahim, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2023-190517

Published: 2023

Journal Articles

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Noemie Leblay, Sungwoo Ahn, Sheri Skerget, Rémi Tilmont, Holly Lee, Mansour Poorebrahim, Daniel Penaherrera, Elie Barakat, David Jung, Nizar J Bahlis, Jonathan Keats, Paola Neri

Blood (2023) 142 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2023-189567

Published: 2023

Journal Articles

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 604–605.

https://doi.org/10.1182/blood-2022-169721

Published: 2022

Journal Articles

CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Remi Tilmont, Ranjan Maity, Noemie Leblay, Holly Lee, Elie Barakat, Paola Neri, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 9964–9965.

https://doi.org/10.1182/blood-2022-169550

Published: 2022

Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran

Blood (2022) 140 (Supplement 1): 10685–10686.

https://doi.org/10.1182/blood-2022-169917

Published: 2022

Journal Articles

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Holly Lee, Paola Neri, Sungwoo Ahn, Ranjan Maity, Noemie Leblay, Bachisio Ziccheddu, Monika Chojnacka, Rémi Tilmont, Elie Barakat, Ola Landgren, Francesco Maura, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 252–253.

https://doi.org/10.1182/blood-2022-167602

Published: 2022

NARROW

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Plasma cells’ fate: it is a complex “orchestra”

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

TP53 function over forms in multiple myeloma

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only